Patents Assigned to AstaZeneca AB
  • Patent number: 11897869
    Abstract: Disclosed herein are compounds of Formula (I), and pharmaceutically acceptable salts thereof, wherein R1-R8 have any of the meanings defined herein. Also disclosed are pharmaceutical compositions comprising compounds of Formula (I) and methods of using the same.
    Type: Grant
    Filed: March 1, 2021
    Date of Patent: February 13, 2024
    Assignee: AstaZeneca AB
    Inventors: Karl Magnus Nilsson, Annika Birgitta Margareta Åstrand, Anna Ingrid Kristina Berggren, Johan R. Johansson, Matti Juhani Lepistö, Sameer Pralhad Kawatkar, Qibin Su, Jason Grant Kettle
  • Patent number: 10858336
    Abstract: The present invention relates to certain 2-(2,4,5-substituted-anilino)pyrimidine compounds and pharmaceutically acceptable salts thereof which may be useful in the treatment or prevention of a disease or medical condition mediated through certain mutated forms of epidermal growth factor receptor (for example the L858R activating mutant, the Exon19 deletion activating mutant and the T790M resistance mutant). Such compounds and salts thereof may be useful in the treatment or prevention of a number of different cancers. The invention also relates to pharmaceutical compositions comprising said compounds and salts thereof, especially useful polymorphic forms of these compounds and salts, intermediates useful in the manufacture of said compounds and to methods of treatment of diseases mediated by various different forms of EGFR using said compounds and salts thereof.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: December 8, 2020
    Assignee: AstaZeneca AB
    Inventors: Sam Butterworth, Maurice Raymond Verschoyle Finlay, Richard Andrew Ward, Heather Marie Redfearn, Vasantha Krishna Kadambar, Chandrasekhara Reddy Chintakuntla, Andiappan Murugan, Claudio Edmundo Chuaqui